Amgen's $2B Monopoly Just Got a Lot Less Comfortable

That's the difference between eight clinic visits and three shots at home. If you're a patient juggling work, kids, and a condition that makes your eyes feel like they're being pushed out of your skull, that convenience gap matters enormously.

Wall Street Wasn't Exactly Popping Champagne

You'd think back-to-back Phase 3 wins would have investors doing cartwheels. Instead, Viridian's stock dropped 26.8% after the initial REVEAL-1 data release in March 2026. What gives?

The issue wasn't whether the drug works. It clearly does. The concern was how much better it looks versus existing options, particularly on secondary endpoints like the clinical activity score (which measures inflammation). On that measure, the every-4-weeks arm hit 57% versus 50% for placebo, a gap that wasn't statistically significant.

Analysts noticed. HC Wainwright slashed their price target from $34 to $22. Goldman Sachs went from $41 to $36. Wedbush trimmed to $31. The consensus: the data is good, maybe not transformative enough to guarantee a clean Tepezza kill.

Still, 13 out of 15 covering analysts maintain Buy ratings. The average price target of $37 implies plenty of upside from recent trading levels. The bulls aren't gone; they're just recalibrating.

The Bigger Picture: A $2 Billion Market Gets Crowded

Tepezza pulled in $1.9 billion in 2024 revenue, making it one of Amgen's most important acquisitions from the Horizon deal. But the market dynamics are shifting.

The market isn't just about stealing share from Tepezza; it's about expanding the pie. A simpler, at-home treatment could pull in patients who've been avoiding the infusion center.

Viridian isn't the only challenger, either. Sling Therapeutics is developing linsitinib, an oral IGF-1R inhibitor. If that pans out, TED patients could eventually choose between an IV infusion, a subcutaneous shot, or a pill. Competition like that tends to be great for patients and rough for incumbents.

What Comes Next

Viridian has two major catalysts ahead. REVEAL-2 data (testing elegrobart in chronic TED, not just active disease) is expected this quarter. That's a population Tepezza hasn't formally cracked, and it could represent a significant market expansion if the results hold up.

After that, if approved, elegrobart would become the first subcutaneous option for TED and the first real alternative to Tepezza since Tepezza's approval in 2020.

For Amgen, the playbook is familiar: expand internationally (Japan approved Tepezza in September 2024, Europe granted marketing authorization in June 2025), keep growing the prescriber base, and hope that first-mover advantage counts for something when a more convenient competitor arrives.

For patients, though, this is unambiguously good news. More options, more convenience, and potentially more price competition in a disease that's been a one-drug town for too long. That's what clinical progress looks like when the market works as intended.